DNA
Price
$11.33
Change
+$0.31 (+2.81%)
Updated
Sep 3 closing price
Capitalization
670.73M
NTLA
Price
$11.71
Change
+$0.31 (+2.72%)
Updated
Sep 3 closing price
Capitalization
1.26B
63 days until earnings call
Interact to see
Advertisement

DNA vs NTLA

Header iconDNA vs NTLA Comparison
Open Charts DNA vs NTLABanner chart's image
Ginkgo Bioworks Holdings
Price$11.33
Change+$0.31 (+2.81%)
Volume$1.49M
Capitalization670.73M
Intellia Therapeutics
Price$11.71
Change+$0.31 (+2.72%)
Volume$4.68M
Capitalization1.26B
DNA vs NTLA Comparison Chart in %
Loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNA vs. NTLA commentary
Sep 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Buy and NTLA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 04, 2025
Stock price -- (DNA: $11.02 vs. NTLA: $11.40)
Brand notoriety: DNA and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 164% vs. NTLA: 76%
Market capitalization -- DNA: $670.73M vs. NTLA: $1.26B
DNA [@Biotechnology] is valued at $670.73M. NTLA’s [@Biotechnology] market capitalization is $1.26B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.69B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both DNA and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 2 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • DNA’s TA Score: 2 bullish, 5 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than DNA.

Price Growth

DNA (@Biotechnology) experienced а -13.77% price change this week, while NTLA (@Biotechnology) price change was +0.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +32.67%.

Reported Earning Dates

NTLA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.26B) has a higher market cap than DNA($671M). DNA YTD gains are higher at: 12.220 vs. NTLA (-2.230). DNA has higher annual earnings (EBITDA): -292.97M vs. NTLA (-501.87M). DNA (474M) and NTLA (460M) have equal amount of cash in the bank . NTLA has less debt than DNA: NTLA (103M) vs DNA (429M). DNA has higher revenues than NTLA: DNA (231M) vs NTLA (52.9M).
DNANTLADNA / NTLA
Capitalization671M1.26B53%
EBITDA-292.97M-501.87M58%
Gain YTD12.220-2.230-548%
P/E RatioN/AN/A-
Revenue231M52.9M437%
Total Cash474M460M103%
Total Debt429M103M417%
FUNDAMENTALS RATINGS
NTLA: Fundamental Ratings
NTLA
OUTLOOK RATING
1..100
69
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
49
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNANTLA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 13 days ago
82%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 14 days ago
87%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRLWX24.44-0.11
-0.45%
Nuveen Large Cap Value W
RYRHX56.48-0.33
-0.58%
Rydex Russell 2000 H
MUSEX39.88-0.26
-0.65%
MFS Blended Research Core Equity I
CMLIX50.91-0.37
-0.72%
Congress Large Cap Growth Institutional
TPLNX19.72-0.16
-0.80%
Timothy Plan Small Cap Value A

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with RXRX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-13.02%
RXRX - DNA
53%
Loosely correlated
-0.85%
ABCL - DNA
49%
Loosely correlated
-3.11%
CRSP - DNA
49%
Loosely correlated
+1.60%
ABSI - DNA
48%
Loosely correlated
-2.09%
NTLA - DNA
48%
Loosely correlated
+0.40%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been loosely correlated with CRSP. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NTLA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
+0.40%
CRSP - NTLA
65%
Loosely correlated
+1.60%
BEAM - NTLA
64%
Loosely correlated
-0.31%
RXRX - NTLA
55%
Loosely correlated
-0.85%
ABCL - NTLA
52%
Loosely correlated
-3.11%
IDYA - NTLA
51%
Loosely correlated
+3.79%
More